Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNL310 long-term open-label extension in MPS II
2023-503837-23-00Phase 3Authorised
- Sponsor
- Denali Therapeutics Inc.
- Start
- Dec 2023
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 15
01
Overview
Phase 3, open-label, single-arm trial of tividenofusp alfa in mucopolysaccharidosis type 2, sponsored by Denali Therapeutics Inc. Primary endpoints: Incidence and intensity of treatment emergent adverse events and Incidence and intensity of infusion related reactions. Planned start Dec 2023; status: authorised.
02
Drugs
tividenofusp alfa
03
Conditions
mucopolysaccharidosis type 2
Beyond the preview
Go deeper on 2023-503837-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503837-23-00.